FDA Warning Letter Hits Distributor McKesson For Allowing Diversion Of Opioids And Other Medications
Executive Summary
FDA has issued its first warning letter under DSCSA to San Francisco-based distributor McKesson Corp. for failing to exercise adequate control over products that were tampered with while stored in its facility. The firm was also chastised for its lax response to reports from pharmacies that opioids and other prescription drugs were removed from bottles and replaced with other drugs while the bottles were in its possession.
You may also be interested in...
COVID-19 Could Offer Some DSCSA Enforcement Relief For Manufacturers
As the US FDA focuses on COVID-19 pandemic-related activities, the time may be right to ask for an extension in complying with the DSCSA’s saleable returns verification deadline.
The Quality Lowdown: Diversion, Cross-Contamination And PR Mix-Ups
McKesson meets with US FDA over opioid diversion warning letter, while UK MHRA takes risk-based approach to cross-contamination recalls and firm says it’s the other Guardian Pharmacy.
Industry Groups Seek More Options In Responding To DSCSA Verification Requests
PhRMA and AAM suggest the US FDA should give pharmaceutical manufacturers more time to respond to requests from trading partners to verify that suspect and illegitimate products had been received. They point out that while DSCSA requires responses to verification requests be made within 24 hours, the law allows FDA to make exceptions.